Thiamine-containing compound metabolic process

Across TCGA cell cohorts, RNA activity of the Thiamine-containing compound metabolic process pathway is significantly associated with the drug response of multiple features, with the BLOOD_Leukemia cohort showing a particularly strong set of associations.

The most reproducible pathway-associated features across cancer lineages are SB216763, CCT007093, and Wee1 Inhibitor, each associated with the pathway in up to 2 cancer types. Since the analysis shows associations rather than directional relationships, both pathway-to-partner and partner-to-pathway views are reported.

Each partner is linked to its corresponding Q-omics profile. The box plot shows the strongest association, SB216763 grouped by Thiamine-containing compound metabolic process-low versus -high activity in BLOOD_Leukemia.

Pathway-associated features by consensus

Ranked by combined sampling and lineage consensus. X-score (pathway→partner) and Y-score (partner→pathway) are standardized regression coefficients; both directions are reported because the association is undirected. The reported p-values are derived from the association test.

Lineage	Partner feature	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
BLOOD_Leukemia	SB216763 →	-1.061	-0.700	.021	.037	3	2
BLOOD_Leukemia	CCT007093 →	-0.476	-0.669	.002	.008	3	2
LUNG_SCLC	Wee1 Inhibitor →	-0.665	-0.522	.012	.013	2	2
LUNG_SCLC	Alisertib →	-2.489	-0.410	.023	.017	2	2
LUNG_SCLC	MK-1775 →	-0.995	-0.522	.013	.013	2	2
LUNG_SCLC	FGFR_3831 →	-1.094	-0.410	.011	.017	2	2

Each partner links to its Q-omics profile. Showing the 6 strongest associations by consensus.

SB216763 by Thiamine-containing compound metabolic process activity — BLOOD_Leukemia

Explore this box plot interactively →